RxDoctor Payments Data

Kyle Lemond, MD

Family Medicine · Evansville, INNPI 1609303015

Payments from drug & device makers

$6,169in general payments, 2019–2025

Across 383 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$550
  • AstraZeneca$512
  • Pfizer$490
  • Novo Nordisk$457
  • Amgen$380
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$6,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,169 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$41,338
Medicare patients
110
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$57,502
OzempicSemaglutide43$47,287
EliquisApixaban26$37,537
JardianceEmpagliflozin38$33,291
RybelsusSemaglutide19$29,387
JanuviaSitagliptin Phosphate20$28,819
MounjaroTirzepatide20$23,527
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,687
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,579
Atorvastatin Calcium348$2,252
Venlafaxine Hcl ErVenlafaxine Hcl39$1,580
Duloxetine Hcl89$1,431
Easy Comfort Pen NeedlePen Needle, Diabetic15$1,392
Gabapentin44$1,274
Omeprazole107$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$457$76,67462 claims
AstraZenecaFarxiga, Breztri Aerosphere$512$72,18981 claims
PfizerEliquis$490$37,53726 claims
MerckJanuvia$161$28,81920 claims
Lilly USA, LLCMounjaro$247$23,52720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →